Compare HBNC & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HBNC | TYRA |
|---|---|---|
| Founded | 1873 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 883.5M | 844.2M |
| IPO Year | N/A | 2021 |
| Metric | HBNC | TYRA |
|---|---|---|
| Price | $17.29 | $21.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $19.67 | ★ $31.20 |
| AVG Volume (30 Days) | 236.6K | ★ 496.7K |
| Earning Date | 01-21-2026 | 11-05-2025 |
| Dividend Yield | ★ 3.69% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | $51.78 | N/A |
| Revenue Next Year | $7.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.91 | N/A |
| 52 Week Low | $12.70 | $6.42 |
| 52 Week High | $18.54 | $22.83 |
| Indicator | HBNC | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 65.96 | 68.26 |
| Support Level | $16.95 | $20.08 |
| Resistance Level | $17.61 | $22.83 |
| Average True Range (ATR) | 0.37 | 1.61 |
| MACD | 0.11 | 0.12 |
| Stochastic Oscillator | 85.08 | 84.28 |
Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.